Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye

  • Authors: Yılmaz E.1, Kurt A.2, Dogruel M.1, Sevgi D.3, Karaosmanoglu H.4, Zerdali E.5, Meric Koc M.6, Mete B.2, Tabak F.2
  • Affiliations:
    1. Tissue Typing Laboratory, Cerrahpasa Medical School, Istanbul University-Cerahpasa
    2. Infectious Diseases and Clinical Microbiology Department, Cerrahpasa Medical School, Istanbul University-Cerahpasa
    3. Infectious Diseases and Clinical Microbiology Department, University of Medical Sciences- Hamidiye Sisli Etfal Research and Training Hospital
    4. Infectious Diseases and Clinical Microbiology Department, University of Medical Sciences-Bakırkoy Dr. Sadi Konuk Research and Training Hospital
    5. Infectious Diseases and Clinical Microbiology Department, University of Medical Sciences-Haseki Research and Training Hospital
    6. Infectious Diseases and Clinical Microbiology Department, Medical School, Bezmialem Vakif University
  • Issue: Vol 22, No 4 (2024)
  • Pages: 266-269
  • Section: Medicine
  • URL: https://rjsvd.com/1570-162X/article/view/644127
  • DOI: https://doi.org/10.2174/011570162X316158240801060941
  • ID: 644127

Cite item

Full Text

Abstract

Introduction:Abacavir is among the first-line initial antiretroviral regimens for most patients living with HIV/AIDS (PLWHA). Although well tolerated, it is associated with hypersensitivity reaction (HSR), which is treatment-limiting and potentially life-threatening. HSR was shown to be associated with the class I MHC allele, HLA-B*57:01. In this study, we aimed to evaluate the prevalence of HLA-B*57:01 in PLWHA in Istanbul, Türkiye.

Material and Methods:Five HIV treatment centers in Istanbul included all sequential treatment-- naïve, ≥ 18 years adult PLWHA, between December 2017- December 2021. Demographic, clinical, and laboratory data were collected at baseline and during treatment. HLA-B* 57:01 genotyping was determined with PCR-SSP.

Results:Eight hundred sixty-seven PLWHA were included (male:91%, mean age 39.6±11.1 years). 1.6% of patients were found to be HLA-B*57:01 positive. Among HLA-B*57:01 positive patients, 4 were initially given abacavir-containing treatment; they were switched to non-abacavir treatment upon the allele found to be positive.

Conclusion:Although previous studies reported the HLA-B*57:01 prevalence of PLWHA in Türkiye as 3-3.6%, we have found the prevalence to be 1.6%. The current study includes higher numbers of patients than the previous studies. Furthermore, patients from all over the country apply to the centers in Istanbul; compared to the other studies, which involve patients limited to the relevant regions, it can be assumed that the number in our cohort is more representative of the country. In conclusion, the prevalence of the HLA-B*57:01 allele in PLWHA in this study is relatively low. With evident benefit in preventing abacavir HSR, HLA-B*57:01 should be screened in planning antiretroviral therapy.

About the authors

Erkan Yılmaz

Tissue Typing Laboratory, Cerrahpasa Medical School, Istanbul University-Cerahpasa

Email: info@benthamscience.net

Ahmet Kurt

Infectious Diseases and Clinical Microbiology Department, Cerrahpasa Medical School, Istanbul University-Cerahpasa

Author for correspondence.
Email: info@benthamscience.net

Mehtap Dogruel

Tissue Typing Laboratory, Cerrahpasa Medical School, Istanbul University-Cerahpasa

Email: info@benthamscience.net

Dilek Sevgi

Infectious Diseases and Clinical Microbiology Department, University of Medical Sciences- Hamidiye Sisli Etfal Research and Training Hospital

Email: info@benthamscience.net

Hayat Karaosmanoglu

Infectious Diseases and Clinical Microbiology Department, University of Medical Sciences-Bakırkoy Dr. Sadi Konuk Research and Training Hospital

Email: info@benthamscience.net

Esra Zerdali

Infectious Diseases and Clinical Microbiology Department, University of Medical Sciences-Haseki Research and Training Hospital

Email: info@benthamscience.net

Meliha Meric Koc

Infectious Diseases and Clinical Microbiology Department, Medical School, Bezmialem Vakif University

Email: info@benthamscience.net

Bilgul Mete

Infectious Diseases and Clinical Microbiology Department, Cerrahpasa Medical School, Istanbul University-Cerahpasa

Email: info@benthamscience.net

Fehmi Tabak

Infectious Diseases and Clinical Microbiology Department, Cerrahpasa Medical School, Istanbul University-Cerahpasa

Email: info@benthamscience.net

References

  1. U.S. Department of Health and human services, panel on antiretroviral guidelines for adults and adolescents. guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2021. Available From: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines
  2. European AIDS Clinical Society Guidelines. GUIDELINES: Version 11.1, October 2022. 2022. Available From: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf
  3. Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: An update. Ann Pharmacother 2008; 42(3): 387-96. doi: 10.1345/aph.1K522 PMID: 18303141
  4. Ma JD, Lee KC, Kuo GM. HLA-B*5701 testing to predict abacavir hypersensitivity. PLoS Curr 2010; 2: RRN1203. doi: 10.1371/currents.RRN1203 PMID: 21151380
  5. Martin MA, Kroetz DL. Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy 2013; 33(7): 765-75. doi: 10.1002/phar.1278 PMID: 23649914
  6. Kolou M, Poda A, Diallo Z, et al. Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa. BMC Immunol 2021; 22(1): 48. doi: 10.1186/s12865-021-00427-7 PMID: 34294032
  7. Orkin C, Sadiq ST, Rice L, Jackson F. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B * 5701 in HIV-1-infected UK subjects. HIV Med 2010; 11(3): 187-92. doi: 10.1111/j.1468-1293.2009.00762.x PMID: 19780860
  8. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: A practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003; 8(2): 36-41. PMID: 12838163
  9. Deveci̇ A, Çoban AY, Durupinar B. HIV ile enfekte hastalarda insan lökosit antijeni (HLA)-B*57:01 prevalansı. Mikrobiyol Bul 2016; 50(4): 544-51. doi: 10.5578/mb.29179 PMID: 28124959
  10. Büyüktuna SA, Öksüz C, Tahmaz A, et al. Distribution of the Prevalence of human leukocyte antigen (HLA)-B*57:01 positivity in HIV-1 Infected individuals and its effects on treatment: Türkiye map-buhasder working group. Mikrobiyol Bul 2024; 58(1): 29-38. doi: 10.5578/mb.20249903 PMID: 38263938
  11. Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B. Studies on abacavir-induced hypersensitivity reaction: A successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci 2013; 56(2): 119-24. doi: 10.1007/s11427-013-4438-8 PMID: 23393027
  12. Mounzer K, Hsu R, Fusco JS, et al. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: A cohort study. AIDS Res Ther 2019; 16(1): 1. doi: 10.1186/s12981-019-0217-3 PMID: 30651100
  13. Stainsby CM, Perger TM, Vannappagari V, et al. Abacavir hypersensitivity reaction reporting rates during a decade of HLA-B*5701 screening as a risk-mitigation measure. Pharmacotherapy 2019; 39(1): 40-54. doi: 10.1002/phar.2196 PMID: 30414209
  14. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486(7404): 554-8. doi: 10.1038/nature11147 PMID: 22722860
  15. Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 2012; 109(25): 9959-64. doi: 10.1073/pnas.1207934109 PMID: 22645359
  16. Darbas S, Inan D, Kilinc Y, et al. Relationship of HLA-B alleles on susceptibility to and protection from HIV infection in Turkish population. North Clin Istanb 2022; 10(1): 67-73. PMID: 36910436
  17. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14(6): 335-42. doi: 10.1097/00008571-200406000-00002 PMID: 15247625
  18. Arrizabalaga J, Rodriguez-Alcántara F, Castañer JL, et al. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study). HIV Clin Trials 2009; 10(1): 48-51. doi: 10.1310/hct1001-48 PMID: 19362996
  19. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45(1): 1-3. doi: 10.1097/QAI.0b013e318046ea31 PMID: 17356469
  20. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22(15): 2025-33. doi: 10.1097/QAD.0b013e3283103ce6 PMID: 18784465
  21. To SWC, Chen JHK, Wong KH, Chan KCW, Tsang OTY, Yam WC. HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: Is this a practical approach in Han-Chinese? Int J STD AIDS 2013; 24(1): 50-2. doi: 10.1258/ijsa.2012.012102 PMID: 23512513

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers